Posted on 17/11/2009 in Pharmaceutical Company Product News Shire has announced that its Attention-Deficit/Hyperactivity Disorder (ADHD) treatment intuniv (guanfacine) produced no unique adverse affects in a recent clinical trial.
This result was achieved with the combination of intuniv and amphetamine or methylphenidate relative to what was observed with either medication alone.
The drug, which is a non-scheduled, once-daily selective alpha-2A agonist indicated for monotherapy treatment of ADHD, is designed for use in children aged between six and 17 years old.
Andrew Cutler, courtesy assistant professor at the department of psychiatry at the University of Florida, said: "The publication of these safety data gives us insight into administering intuniv in combination with stimulant medications in the management of ADHD."
Another ADHD treatment produced by Shire - vyvanse - also demonstrated significant improvement in symptoms among children aged six to 12 years, the firm reported last week.
During the trial, symptoms were evaluated according to the ADHD Rating Scale IV, as well as Connors' Parent Rating Scale-Revised Short.
Other news stories from 17/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
